Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Residence Characteristics | 14 | 2025 | 290 | 3.480 |
Why?
|
| Socioeconomic Factors | 12 | 2025 | 908 | 1.950 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2024 | 998 | 1.740 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1405 | 1.550 |
Why?
|
| Texas | 23 | 2025 | 3664 | 1.290 |
Why?
|
| Cyclonic Storms | 4 | 2023 | 80 | 1.190 |
Why?
|
| Transportation | 2 | 2019 | 29 | 1.030 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2024 | 260 | 1.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 818 | 0.930 |
Why?
|
| Schools | 6 | 2025 | 238 | 0.860 |
Why?
|
| Walking | 4 | 2019 | 233 | 0.820 |
Why?
|
| Environment Design | 4 | 2019 | 17 | 0.810 |
Why?
|
| Pediatric Obesity | 6 | 2025 | 413 | 0.800 |
Why?
|
| Floods | 3 | 2022 | 18 | 0.790 |
Why?
|
| Registries | 7 | 2024 | 1582 | 0.780 |
Why?
|
| Arsenic | 1 | 2023 | 48 | 0.780 |
Why?
|
| Health Status Disparities | 4 | 2024 | 252 | 0.780 |
Why?
|
| Social Class | 3 | 2025 | 207 | 0.700 |
Why?
|
| Disasters | 1 | 2021 | 106 | 0.630 |
Why?
|
| Public Facilities | 1 | 2019 | 2 | 0.620 |
Why?
|
| Bicycling | 1 | 2019 | 36 | 0.600 |
Why?
|
| Hypersensitivity | 1 | 2021 | 195 | 0.580 |
Why?
|
| Incidence | 8 | 2024 | 3385 | 0.570 |
Why?
|
| Geographic Information Systems | 2 | 2015 | 41 | 0.570 |
Why?
|
| Overweight | 1 | 2020 | 386 | 0.550 |
Why?
|
| Stress, Psychological | 2 | 2021 | 604 | 0.530 |
Why?
|
| Pandemics | 5 | 2023 | 1192 | 0.510 |
Why?
|
| Mexican Americans | 2 | 2015 | 169 | 0.500 |
Why?
|
| Exercise | 2 | 2019 | 873 | 0.470 |
Why?
|
| Communicable Disease Control | 5 | 2023 | 142 | 0.440 |
Why?
|
| Safety | 2 | 2016 | 217 | 0.440 |
Why?
|
| Humans | 52 | 2025 | 133192 | 0.420 |
Why?
|
| Male | 42 | 2025 | 65480 | 0.420 |
Why?
|
| Female | 37 | 2025 | 71395 | 0.420 |
Why?
|
| Spatial Analysis | 2 | 2024 | 26 | 0.400 |
Why?
|
| Health Behavior | 4 | 2020 | 400 | 0.390 |
Why?
|
| Adult | 18 | 2024 | 31617 | 0.370 |
Why?
|
| Fenfluramine | 3 | 1997 | 12 | 0.360 |
Why?
|
| Motor Activity | 2 | 2014 | 528 | 0.350 |
Why?
|
| Parents | 2 | 2016 | 1073 | 0.340 |
Why?
|
| Environmental Exposure | 2 | 2024 | 236 | 0.330 |
Why?
|
| Middle Aged | 13 | 2024 | 28912 | 0.310 |
Why?
|
| Analgesics | 4 | 1994 | 131 | 0.300 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 3735 | 0.280 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 571 | 0.280 |
Why?
|
| Surveys and Questionnaires | 10 | 2024 | 3985 | 0.270 |
Why?
|
| United States | 14 | 2025 | 11711 | 0.270 |
Why?
|
| Adolescent | 15 | 2025 | 20550 | 0.270 |
Why?
|
| Child | 16 | 2025 | 25849 | 0.260 |
Why?
|
| Aged | 9 | 2024 | 21448 | 0.250 |
Why?
|
| Young Adult | 8 | 2024 | 9921 | 0.240 |
Why?
|
| Child, Preschool | 8 | 2024 | 14865 | 0.240 |
Why?
|
| Social Environment | 2 | 2016 | 124 | 0.230 |
Why?
|
| Sex Characteristics | 3 | 2023 | 334 | 0.230 |
Why?
|
| Research Design | 5 | 2020 | 757 | 0.230 |
Why?
|
| Culex | 1 | 2024 | 34 | 0.220 |
Why?
|
| Mosquito Vectors | 1 | 2024 | 37 | 0.220 |
Why?
|
| Geography, Medical | 1 | 2023 | 16 | 0.210 |
Why?
|
| Serotonin | 2 | 1994 | 222 | 0.200 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 106 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 157 | 0.200 |
Why?
|
| Hypothalamus | 2 | 1994 | 223 | 0.190 |
Why?
|
| Wounds, Gunshot | 1 | 2024 | 147 | 0.190 |
Why?
|
| Pain | 4 | 2022 | 469 | 0.190 |
Why?
|
| Endocrine Disruptors | 1 | 2022 | 54 | 0.190 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 215 | 0.190 |
Why?
|
| Machine Learning | 1 | 2025 | 345 | 0.180 |
Why?
|
| Peritoneal Dialysis | 1 | 2023 | 132 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 297 | 0.180 |
Why?
|
| Health Services Accessibility | 3 | 2025 | 658 | 0.180 |
Why?
|
| Arginine Vasopressin | 2 | 1992 | 29 | 0.180 |
Why?
|
| Sociological Factors | 1 | 2021 | 9 | 0.180 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2022 | 77 | 0.180 |
Why?
|
| Workplace Violence | 1 | 2020 | 3 | 0.170 |
Why?
|
| Social Isolation | 1 | 2020 | 48 | 0.170 |
Why?
|
| Program Evaluation | 3 | 2023 | 460 | 0.170 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 81 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 504 | 0.160 |
Why?
|
| House Calls | 1 | 2020 | 38 | 0.160 |
Why?
|
| Public Opinion | 1 | 2020 | 62 | 0.160 |
Why?
|
| Receptors, Serotonin | 2 | 1997 | 43 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 397 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 190 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 187 | 0.150 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1887 | 0.150 |
Why?
|
| Cities | 1 | 2019 | 51 | 0.150 |
Why?
|
| Stress, Physiological | 2 | 1991 | 270 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 216 | 0.150 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 260 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 130 | 0.150 |
Why?
|
| Outpatients | 1 | 2020 | 275 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2021 | 395 | 0.150 |
Why?
|
| Survivors | 1 | 2020 | 358 | 0.140 |
Why?
|
| Educational Status | 2 | 2021 | 294 | 0.140 |
Why?
|
| Health Status | 1 | 2020 | 414 | 0.140 |
Why?
|
| Social Media | 1 | 2020 | 120 | 0.140 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 131 | 0.140 |
Why?
|
| Community Networks | 1 | 2017 | 33 | 0.140 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1997 | 3 | 0.140 |
Why?
|
| Interleukin-1 | 2 | 1995 | 139 | 0.140 |
Why?
|
| Thiazepines | 1 | 1997 | 8 | 0.130 |
Why?
|
| Mental Health | 1 | 2020 | 377 | 0.130 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1997 | 26 | 0.130 |
Why?
|
| Eating | 2 | 1997 | 393 | 0.130 |
Why?
|
| Appetite Depressants | 1 | 1997 | 23 | 0.130 |
Why?
|
| Fluoxetine | 1 | 1997 | 46 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 306 | 0.130 |
Why?
|
| Behavior, Animal | 3 | 1997 | 522 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2025 | 17526 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 466 | 0.130 |
Why?
|
| Attitude to Health | 2 | 2015 | 261 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2023 | 892 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 441 | 0.130 |
Why?
|
| Mice, Inbred Strains | 6 | 1995 | 317 | 0.120 |
Why?
|
| Hypertension | 1 | 2025 | 1402 | 0.120 |
Why?
|
| Neoplasms | 3 | 2024 | 2984 | 0.120 |
Why?
|
| Indomethacin | 1 | 1995 | 84 | 0.120 |
Why?
|
| Prednisolone | 1 | 1995 | 70 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 638 | 0.120 |
Why?
|
| Norfenfluramine | 1 | 1994 | 1 | 0.110 |
Why?
|
| Survival Rate | 1 | 2020 | 2204 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 385 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 395 | 0.110 |
Why?
|
| Family Relations | 1 | 2015 | 71 | 0.110 |
Why?
|
| Naloxone | 2 | 1991 | 50 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 483 | 0.110 |
Why?
|
| School Health Services | 1 | 2015 | 102 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2014 | 93 | 0.110 |
Why?
|
| Feeding and Eating Disorders | 1 | 1994 | 76 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5435 | 0.110 |
Why?
|
| Physicians | 1 | 2020 | 640 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2015 | 180 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2015 | 222 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 313 | 0.100 |
Why?
|
| Receptors, Vasopressin | 1 | 1992 | 12 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1995 | 314 | 0.100 |
Why?
|
| Body Temperature Regulation | 1 | 1992 | 51 | 0.100 |
Why?
|
| Dopamine | 1 | 1994 | 285 | 0.100 |
Why?
|
| Codeine | 1 | 1992 | 23 | 0.090 |
Why?
|
| Asthma | 1 | 2020 | 807 | 0.090 |
Why?
|
| Behavioral Medicine | 1 | 2011 | 11 | 0.090 |
Why?
|
| Morphine | 1 | 1992 | 87 | 0.090 |
Why?
|
| Students | 1 | 2014 | 263 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1992 | 138 | 0.090 |
Why?
|
| Models, Educational | 1 | 2011 | 76 | 0.090 |
Why?
|
| Histamine | 1 | 1991 | 49 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1990 | 9 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 804 | 0.090 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1990 | 38 | 0.090 |
Why?
|
| Prognosis | 1 | 2020 | 5032 | 0.080 |
Why?
|
| Analgesia | 1 | 1990 | 46 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1514 | 0.080 |
Why?
|
| Research Personnel | 1 | 2011 | 136 | 0.080 |
Why?
|
| Nociceptors | 1 | 1990 | 15 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 1994 | 828 | 0.080 |
Why?
|
| Injections, Intraventricular | 4 | 1992 | 64 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 2628 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 1994 | 726 | 0.070 |
Why?
|
| Animals | 12 | 2024 | 36191 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2014 | 1710 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 1303 | 0.070 |
Why?
|
| Inflammation | 1 | 1995 | 1556 | 0.070 |
Why?
|
| Brain | 2 | 1997 | 3223 | 0.060 |
Why?
|
| Pain Measurement | 3 | 1994 | 365 | 0.060 |
Why?
|
| Linear Models | 2 | 2021 | 719 | 0.060 |
Why?
|
| Sex Factors | 2 | 2021 | 1350 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2011 | 551 | 0.060 |
Why?
|
| Population Density | 1 | 2024 | 34 | 0.060 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 9 | 0.060 |
Why?
|
| Rats | 3 | 1997 | 3850 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3087 | 0.050 |
Why?
|
| Risk Factors | 3 | 2025 | 10936 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2025 | 270 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2023 | 36 | 0.050 |
Why?
|
| Environmental Health | 1 | 2023 | 16 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 2954 | 0.050 |
Why?
|
| Mice | 8 | 1995 | 18930 | 0.050 |
Why?
|
| Sarcoma, Ewing | 1 | 2024 | 116 | 0.050 |
Why?
|
| Firearms | 1 | 2024 | 57 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2024 | 139 | 0.050 |
Why?
|
| Focus Groups | 1 | 2023 | 215 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 172 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 2 | 1994 | 74 | 0.050 |
Why?
|
| Silicones | 1 | 2022 | 33 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 125 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2022 | 85 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2022 | 76 | 0.050 |
Why?
|
| Hepatoblastoma | 1 | 2024 | 183 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2021 | 32 | 0.050 |
Why?
|
| Marital Status | 1 | 2021 | 32 | 0.040 |
Why?
|
| Physical Exertion | 2 | 1991 | 78 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2023 | 201 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1862 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 366 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 148 | 0.040 |
Why?
|
| Hot Temperature | 2 | 1991 | 145 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 27 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 82 | 0.040 |
Why?
|
| Fever | 1 | 2022 | 312 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 216 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 1714 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 125 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1468 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 1019 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 177 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 552 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 413 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 255 | 0.040 |
Why?
|
| Infant | 2 | 2024 | 13237 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 104 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 242 | 0.040 |
Why?
|
| Life Style | 1 | 2021 | 457 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 283 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 236 | 0.030 |
Why?
|
| Serotonin Agents | 1 | 1997 | 15 | 0.030 |
Why?
|
| Neuropeptide Y | 1 | 1997 | 34 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1997 | 122 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 683 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 1997 | 80 | 0.030 |
Why?
|
| Zymosan | 1 | 1995 | 3 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 1995 | 22 | 0.030 |
Why?
|
| Peroxidase | 1 | 1995 | 65 | 0.030 |
Why?
|
| Formaldehyde | 2 | 1992 | 38 | 0.030 |
Why?
|
| Granuloma | 1 | 1995 | 63 | 0.030 |
Why?
|
| Fenclonine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Dinoprostone | 1 | 1995 | 82 | 0.030 |
Why?
|
| Microdialysis | 1 | 1994 | 57 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1620 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2015 | 56 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 904 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2015 | 91 | 0.030 |
Why?
|
| Administration, Oral | 2 | 1994 | 718 | 0.030 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1994 | 9 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1994 | 30 | 0.030 |
Why?
|
| Food Deprivation | 1 | 1994 | 34 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 1994 | 135 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 1994 | 166 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 1994 | 167 | 0.030 |
Why?
|
| Abdomen | 1 | 1994 | 136 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 395 | 0.030 |
Why?
|
| Oxymorphone | 1 | 1992 | 1 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 684 | 0.020 |
Why?
|
| Body Weight | 1 | 1997 | 1035 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1166 | 0.020 |
Why?
|
| Receptors, Histamine | 1 | 1991 | 3 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 1991 | 19 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1991 | 40 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2014 | 331 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 1992 | 112 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 404 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 5191 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8628 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2011 | 145 | 0.020 |
Why?
|
| Swimming | 1 | 1990 | 29 | 0.020 |
Why?
|
| Parenting | 1 | 2015 | 349 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1990 | 174 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2011 | 220 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1990 | 259 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 2160 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2785 | 0.020 |
Why?
|
| Reaction Time | 1 | 1990 | 169 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3960 | 0.020 |
Why?
|
| Cognition | 1 | 2014 | 816 | 0.020 |
Why?
|
| Anxiety | 1 | 2015 | 1006 | 0.020 |
Why?
|
| Arginine | 1 | 1991 | 350 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 2139 | 0.020 |
Why?
|
| HIV Infections | 1 | 2019 | 2060 | 0.020 |
Why?
|
| Diet | 1 | 1994 | 1167 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 7137 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1991 | 61 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1991 | 123 | 0.010 |
Why?
|
| Edema | 1 | 1991 | 147 | 0.000 |
Why?
|
| Nitric Oxide | 1 | 1991 | 487 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1991 | 1411 | 0.000 |
Why?
|